Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;26(1):51-59.
doi: 10.1007/s40291-021-00565-z. Epub 2021 Dec 3.

Achromatopsia: Genetics and Gene Therapy

Stylianos Michalakis  1 , Maximilian Gerhardt  2 , Günther Rudolph  2 , Siegfried Priglinger  2 , Claudia Priglinger  2
Affiliations
Review

Achromatopsia: Genetics and Gene Therapy

Stylianos Michalakis et al. Mol Diagn Ther. 2022 Jan.

Abstract

Achromatopsia (ACHM), also known as rod monochromatism or total color blindness, is an autosomal recessively inherited retinal disorder that affects the cones of the retina, the type of photoreceptors responsible for high-acuity daylight vision. ACHM is caused by pathogenic variants in one of six cone photoreceptor-expressed genes. These mutations result in a functional loss and a slow progressive degeneration of cone photoreceptors. The loss of cone photoreceptor function manifests at birth or early in childhood and results in decreased visual acuity, lack of color discrimination, abnormal intolerance to light (photophobia), and rapid involuntary eye movement (nystagmus). Up to 90% of patients with ACHM carry mutations in CNGA3 or CNGB3, which are the genes encoding the alpha and beta subunits of the cone cyclic nucleotide-gated (CNG) channel, respectively. No authorized therapy for ACHM exists, but research activities have intensified over the past decade and have led to several preclinical gene therapy studies that have shown functional and morphological improvements in animal models of ACHM. These encouraging preclinical data helped advance multiple gene therapy programs for CNGA3- and CNGB3-linked ACHM into the clinical phase. Here, we provide an overview of the genetic and molecular basis of ACHM, summarize the gene therapy-related research activities, and provide an outlook for their clinical application.

PubMed Disclaimer

Conflict of interest statement

SM is co-founder and shareholder of ViGeneron GmbH, a gene therapy company. MG, GR, SP, and CP have no conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Known achromatopsia (ACHM) genes and their functions. A Most genes associated with ACHM encode proteins involved in phototransduction. The most common ACHM genes are CNGA3 and CNGB3, which encode the two subunits of the cyclic nucleotide-gated (CNG) channel, which is located in the plasma membrane of the outer segment. A less common disease gene is GNAT2, which encodes the cone transducin (Gt) that activates the phosphodiesterase (PDE6), which mediates the hydrolysis of the second messenger cyclic guanosine monophosphate (cGMP). The two genes encoding the cone PDE6 (PDE6C and PDE6H) have also been linked to ACHM. B The only known ACHM gene that does not encode a phototransduction cascade protein is ATF6. ATF6 is localized in the endoplasmic reticulum and is involved in endoplasmic reticulum stress and the unfolded protein response. The relative frequencies of ACHM mutations in Europe and Northern America are given next to the boxes with the gene names. Created with BioRender.com. GTP guanosine-triphosphate; retGC receptor guanylyl cyclase
See this image and copyright information in PMC

Similar articles

  • Genetics and Disease Expression in the CNGA3 Form of Achromatopsia: Steps on the Path to Gene Therapy.
    Zelinger L, Cideciyan AV, Kohl S, Schwartz SB, Rosenmann A, Eli D, Sumaroka A, Roman AJ, Luo X, Brown C, Rosin B, Blumenfeld A, Wissinger B, Jacobson SG, Banin E, Sharon D. Zelinger L, et al. Ophthalmology. 2015 May;122(5):997-1007. doi: 10.1016/j.ophtha.2014.11.025. Epub 2015 Jan 21. Ophthalmology. 2015. PMID: 25616768
  • Gene therapy for achromatopsia.
    Michalakis S, Schön C, Becirovic E, Biel M. Michalakis S, et al. J Gene Med. 2017 Mar;19(3). doi: 10.1002/jgm.2944. J Gene Med. 2017. PMID: 28095637 Review.
  • Canine CNGA3 Gene Mutations Provide Novel Insights into Human Achromatopsia-Associated Channelopathies and Treatment.
    Tanaka N, Dutrow EV, Miyadera K, Delemotte L, MacDermaid CM, Reinstein SL, Crumley WR, Dixon CJ, Casal ML, Klein ML, Aguirre GD, Tanaka JC, Guziewicz KE. Tanaka N, et al. PLoS One. 2015 Sep 25;10(9):e0138943. doi: 10.1371/journal.pone.0138943. eCollection 2015. PLoS One. 2015. PMID: 26407004 Free PMC article.
  • Comprehensive variant spectrum of the CNGA3 gene in patients affected by achromatopsia.
    Solaki M, Baumann B, Reuter P, Andreasson S, Audo I, Ayuso C, Balousha G, Benedicenti F, Birch D, Bitoun P, Blain D, Bocquet B, Branham K, Català-Mora J, De Baere E, Dollfus H, Falana M, Giorda R, Golovleva I, Gottlob I, Heckenlively JR, Jacobson SG, Jones K, Jägle H, Janecke AR, Kellner U, Liskova P, Lorenz B, Martorell-Sampol L, Messias A, Meunier I, Belga Ottoni Porto F, Papageorgiou E, Plomp AS, de Ravel TJL, Reiff CM, Renner AB, Rosenberg T, Rudolph G, Salati R, Sener EC, Sieving PA, Stanzial F, Traboulsi EI, Tsang SH, Varsanyi B, Weleber RG, Zobor D, Stingl K, Wissinger B, Kohl S. Solaki M, et al. Hum Mutat. 2022 Jul;43(7):832-858. doi: 10.1002/humu.24371. Epub 2022 Apr 14. Hum Mutat. 2022. PMID: 35332618 Review.
  • Gene Therapy for Achromatopsia.
    Baxter MF, Borchert GA. Baxter MF, et al. Int J Mol Sci. 2024 Sep 9;25(17):9739. doi: 10.3390/ijms25179739. Int J Mol Sci. 2024. PMID: 39273686 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Francois J. Heredity in ophthalmology. Bull Soc Belge Ophtalmol. 1958;118(Pt 1):1–300. - PubMed
    1. Neitz J, Neitz M. The genetics of normal and defective color vision. Vis Res. 2011;51(7):633–651. - PMC - PubMed
    1. Hirji N, Aboshiha J, Georgiou M, Bainbridge J, Michaelides M. Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic Genet. 2018;39(2):149–157. - PubMed
    1. Brunetti-Pierri R, Karali M, Melillo P, Di Iorio V, De Benedictis A, Iaccarino G, et al. Clinical and molecular characterization of achromatopsia patients: a longitudinal study. Int J Mol Sci. 2021;7(22):4. - PMC - PubMed
    1. Andreasson S, Tornqvist K. Electroretinograms in patients with achromatopsia. Acta Ophthalmol (Copenh). 1991;69(6):711–716. - PubMed

Substances

Supplementary concepts